Suche
Mein Konto
Bayer shares in the red: What's behind the price loss and how do analysts assess the situation?
Thursday, February 8th, 2024 10:13 a.m. by ARIVA.DE editorial team Bayer's shares (Bayer shares) are currently in the red. The security last cost 28.06 euros. Today's trading day hasn't gone particularly well for Bayer owners. The paper currently has a price loss of 2.25 percent. Compared to yesterday's closing price, the share price lost 65 cents. The security was last quoted at 28.06 euros. Bayer shares are lagging behind the Euro Stoxx 50 (Euro Stoxx 50). The Euro Stoxx 50 currently has 4,691 points. This corresponds to an increase of 0.26 percent. Despite today's price loss: From its all-time low...
Bayer shares in the red: What's behind the price loss and how do analysts assess the situation?
Thursday, February 8, 2024 10:13 am
fromARIVA.DE editorial team
- Im Minus liegt derzeit der Anteilsschein von Bayer (Bayer-Aktie).
- Das Wertpapier kostete zuletzt 28,06 Euro.
Today's trading day hasn't gone particularly well for Bayer owners. The paper currently has a price loss of 2.25 percent. Compared to yesterday's closing price, the share price lost 65 cents. The security was last quoted at 28.06 euros. Bayer shares are lagging behind the Euro Stoxx 50 (Euro Stoxx 50). The Euro Stoxx 50 currently has 4,691 points. This corresponds to an increase of 0.26 percent. Despite today's price loss, Bayer's shares are currently still a long way from their all-time low. On March 17, 2003, the paper went out of trading at a price of 9.64 euros - 65.62 percent less than the current price.
The Bayer company
Bayer Aktiengesellschaft, together with its subsidiaries, operates worldwide as a life science company. The company operates in the Pharmaceuticals, Consumer Health and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health, specialty therapeutics in the areas of oncology, hematology and ophthalmology, diagnostic imaging devices and contrast media, as well as cell and gene therapy.
That’s what the competition is like
Bayer faces several competitors in the market. For example, BASF shares (BASF shares) are currently in the red. BASF fell in price by 0.22 percent. In contrast, the security of competitor Dupont De Nemours (Dupont De Nemours share) was definitely in demand. Price increase at Dupont De Nemours: 0.32 percent.
This is how analysts see Bayer shares
Bayer's shares are being monitored by several analysts.
The US bank JPMorgan has left Bayer's rating at “neutral” with a price target of 34 euros following a court ruling on the herbicide dicamba. Analyst Richard Vosser pointed out in a study available on Wednesday that the federal court in Arizona canceled the approval for dicamba granted by the US Environmental Protection Agency (EPA). If the drug is withdrawn from the US market, this could have a negative effect of up to two percent on the agrochemical company's operating result in 2025, he wrote.
After a media report on the herbicide dicamba, the analysis firm Jefferies left Bayer's rating at “Hold” with a price target of 37 euros. According to Bloomberg, a federal court in Arizona has canceled the approval granted by the Environmental Protection Agency (EPA), analyst Charlie Bentley wrote in a study available on Wednesday. Its use is therefore prohibited during the season. If the ruling stands, it would have a significant impact on the agar chemicals company, wrote Bentley.
This article was created by ARIVA.DE using stock analyzes from dpa-AFX. Information on the obligation to disclose conflicts of interest within the meaning of Section 34 b of the WpHG for the analyst firms mentioned can be found here.
More topics
How m.ariva.de reported, Bayer shares are currently in the red and have recorded a price loss of 2.25 percent. The current rate is 28.06 euros.
As a financial expert, I view current developments critically. A loss of over 2 percent in one day is alarming and could be due to various factors. JPMorgan's analysis showed that the recent court ruling on the herbicide dicamba could potentially have a negative impact on the agrochemical company's operating results in 2025. If the drug were to be withdrawn from the US market, a negative effect of up to two percent could occur.
The competitive situation in the market and analysts' assessments also indicate that Bayer is facing some challenges. The rating of the share by Jefferies as “Hold” and the price target of 37 euros also suggest a critical assessment.
It is important to continue to closely monitor developments at Bayer and the market reaction, as possible negative impacts on the company and the financial industry as a whole cannot be ruled out.
Read the source article at m.ariva.de